Metastatic breast cancer trials in Brazil

In Brazil 18 Also abroad 610

18 trials · From ClinicalTrials.gov, checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 3Taking people
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
Where
Belém, Belo Horizonte, Fortaleza, Goiânia, Natal, Porto Alegre, Rio de Janeiro, Salvador, São Caetano do Sul, São Paulo
Age
18 years and over
People
540 worldwide
Run by
Relay Therapeutics, Inc.
See details and how to joinNCT06982521 · EU 2025-523083-21-00
Phase 2/3Taking people
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
Where
Brasília, Porto Alegre, Recife, São Carlos, São Paulo, Vitória
Age
18 years and over
People
650 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07413939 · EU 2025-524498-17-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Where
Alfenas, Barretos, Fortaleza, Goiânia, Londrina, Porto Alegre, Recife, Rio de Janeiro, Salvador, São Paulo, Teresina, Vitória
Age
18 years and over
People
450 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT06790693 · EU 2024-516162-11-00
Phase 3Taking people
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Where
Barretos, Bequimão, Fortaleza, Goiânia, Lago Sul, Londrina, Mossoró, Natal, Porto Alegre, Rio de Janeiro, São Paulo
Age
18 years and over
People
800 worldwide
Run by
Eli Lilly and Company
See details and how to joinNCT07174336 · EU 2025-522791-92-00
Phase 3Taking people
A Clinical Study of Patritumab Deruxtecan to Treat Breast Cancer (MK-1022-016)
Where
Lages, Natal, Porto Alegre, Recife, Santa Cruz do Sul, São Paulo
Age
18 years and over
People
1,000 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT07060807 · EU 2025-520582-51-00
Phase 2Taking people
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Where
Brasília, Curitiba, São Paulo, Vitória
Age
18 years and over
People
80 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT07405801 · EU 2025-523013-28-00
Phase 3Taking people
Saruparib (AZD5305) Plus Camizestrant or Plus Endocrine Therapy, Compared With CDK4/6 Inhibitor Plus Endocrine Therapy or Plus Camizestrant in HR-Positive, HER2-Negative (IHC 0, 1+, 2+/ ISH Non-amplified), BRCA1, BRCA2, or PALB2m Advanced Breast Cancer
Where
Cachoeira de Itapemirim, Curitiba, Fortaleza, Goiânia, Jaú, Porto Alegre, Ribeirão Preto, Salvador, São Paulo
Age
18 years and over
People
788 worldwide
Run by
AstraZeneca
See details and how to joinNCT06380751 · EU 2023-504180-16-00
Phase 3Taking people
A Study Evaluating the Efficacy and Safety of Inavolisib Plus Fulvestrant Compared With Alpelisib Plus Fulvestrant in Participants With HR-Positive, HER2-Negative, PIK3CA Mutated, Locally Advanced or Metastatic Breast Cancer Post CDK4/6i and Endocrine Combination Therapy
Where
Belo Horizonte, Brasília, Curitiba, Natal, Porto Alegre, Recife, Salvador, São José do Rio Preto, São Paulo, Teresina
Age
18 years and over
People
420 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05646862 · EU 2022-502322-41-00
Phase 1/2Taking people
A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)
Where
Barretos, Florianópolis, Jaú, Porto Alegre
Age
18 years and over
People
680 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT06330064 · EU 2023-509632-26-00
Phase 3Taking people
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
Where
Ijuí, Lages, Londrina, Porto Alegre, São Caetano do Sul, São Paulo, Vitória
Age
18 years and over
People
400 worldwide
Run by
Pfizer
See details and how to joinNCT07062965 · EU 2025-520566-22-00
Phase 3Taking people
A Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Phesgo Versus Placebo in Combination With Phesgo in Participants With PIK3CA-Mutated HER2-Positive Locally Advanced or Metastatic Breast Cancer
Where
Barretos, Fortaleza, Goiânia, Londrina, Porto Alegre, Porto Velho, Recife, Salvador, São Paulo
Age
18 years and over
People
230 worldwide
Run by
Hoffmann-La Roche
See details and how to joinNCT05894239 · EU 2022-502046-28-00
No phaseTaking people
Minimally Interventional Study on Prevalence of Emerging ESR1 Mutations in Liquid Biopsy in Three Cohorts of Patients With Breast Cancer in Comparison With Patient's Baseline ESR1 Mutation Status as Defined by Tissue Profiling.
Where
Porto Alegre, Salvador, São Paulo
Age
18 years to 100 years
People
170
Run by
AstraZeneca
See details and how to joinNCT06417801
Phase 1Taking people
BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors
Where
Barretos, Brasília, Caxias do Sul, Florianópolis, Natal, Porto Algre, Rio de Janeiro, Salvador, São Paulo
Age
18 years and over
People
433 worldwide
Run by
BeOne Medicines
See details and how to joinNCT06120283 · EU 2023-506888-34-00
Phase 3Taking people
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
Where
Porto Alegre, Santa Cruz do Sul, São Paulo, Taubaté, Teresina
Age
18 years and over
People
1,200 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT06312176 · EU 2023-504918-29-00
Phase 1Taking people
Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Where
Natal, Porto Alegre, São Paulo, Sorocaba
Age
18 years and over
People
392 worldwide
Run by
TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics)
See details and how to joinNCT06625775 · EU 2024-519445-29-00
Phase 3Taking people
Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Where
Bento Gonçalves, Cachoeiro de Itapemirim, Itajaí, Porto Alegre, Salvador
Age
18 years and over
People
300 worldwide
Run by
MedSIR
See details and how to joinNCT06382948 · EU 2024-512926-27-00
Phase 3Taking people
Trastuzumab Deruxtecan (T-DXd) in Patients Who Have Hormone Receptor-negative and Hormone Receptor-positive HER2-low or HER2 IHC 0 Metastatic Breast Cancer
Where
Brasília, Curitiba, Florianópolis, Ijuí, Jaú, Londrina, Riberão Preto, Rio Grande, Salvador, Santa Catarina, Santo André, São José do Rio Preto, São Paulo
Age
18 years and over
People
250 worldwide
Run by
Daiichi Sankyo
See details and how to joinNCT05950945 · EU 2023-505616-38-00
No phaseNot yet taking people in Brazil
Exercise Training in Women With Metastatic Breast Cancer
Where
Londrina
Age
18 years and over
People
78
Run by
State University of Londrina
See details and how to joinNCT07521826